Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Large Insider Purchases

Institutional-Scale SEC Form 4 Buy Signals

The Signal of $1M+ Conviction

When a corporate executive invests more than $1,000,000 of their own capital into company shares, it represents the highest level of conviction. These seven-figure purchases reflect management's belief in the company's future value.

Filing Date Trade Date Ticker Company Name Reporting Person Relationship Industry Type Price Qty Total, $ Owned After Change, %
2020-10-23 02:53 2020-10-20 EAR N/A MAKOWER JOSHUA Director, 10% owner Other BUY $18.00 311,111 $5,599,998 6,520,017 +5.0%
2020-10-23 03:34 2020-10-20 ARYB N/A PERCEPTIVE ADVISORS LLC Director Other BUY $10.02 157,295 $1,576,835 157,295 +100.0%
2020-10-21 20:01 2020-10-19 VTA N/A Saba Capital Management, L.P. 10% owner Other BUY $9.35 602,072 $5,631,059 7,080,122 +9.3%
2020-10-21 20:12 2020-10-19 EFT Eaton Vance Floating-Rate Income Trust Saba Capital Management, L.P. 10% owner Other BUY $12.77 285,528 $3,646,021 4,305,910 +7.1%
2020-10-22 03:55 2020-10-19 TMTSU N/A SUBIN NEIL S 10% owner Other BUY $10.00 500,000 $5,000,000 500,000 +100.0%
2020-10-21 02:59 2020-10-20 TARS Tarsus Pharmaceuticals, Inc. Horowitz Limited Partnership VIII 10% owner Biological Products, (No Diagnostic Substances) BUY $16.00 184,375 $2,950,000 66,172 +100.0%
2020-10-21 02:56 2020-10-20 TARS Tarsus Pharmaceuticals, Inc. Tester Jason E. Director, 10% owner Biological Products, (No Diagnostic Substances) BUY $16.00 171,875 $2,750,000 1,920,933 +9.8%
2020-10-21 02:58 2020-10-20 TARS Tarsus Pharmaceuticals, Inc. Vivo Capital IX, LLC 10% owner Biological Products, (No Diagnostic Substances) BUY $16.00 250,000 $4,000,000 3,245,035 +8.3%
2020-10-20 23:58 2020-10-20 ALGS Aligos Therapeutics Inc. Versant Venture Capital VI, L.P. 10% owner Biological Products, (No Diagnostic Substances) BUY $15.00 200,000 $3,000,000 862,444 +30.2%
2020-10-21 00:00 2020-10-20 ALGS Aligos Therapeutics Inc. Woiwode Thomas Director Biological Products, (No Diagnostic Substances) BUY $15.00 200,000 $3,000,000 862,444 +30.2%
2020-10-20 23:59 2020-10-20 ALGS Aligos Therapeutics Inc. Vivo Capital VIII, LLC 10% owner Biological Products, (No Diagnostic Substances) BUY $15.00 550,000 $8,250,000 430,372 +100.0%
2020-10-21 03:01 2020-10-20 TARS Tarsus Pharmaceuticals, Inc. Frazier Life Sciences IX, L.P. 10% owner Biological Products, (No Diagnostic Substances) BUY $16.00 312,500 $5,000,000 1,917,157 +19.5%
2020-10-20 23:00 2020-10-16 RADI N/A DKLDO IV Trading Subsidiary LP 10% owner Other BUY $8.00 500,000 $4,000,000 6,852,901 +7.9%
2020-10-21 03:03 2020-10-16 CDAK N/A GILLIS STEVEN Director Other BUY $15.00 235,000 $3,525,000 2,503,903 +10.4%
2020-10-21 03:05 2020-10-16 CDAK N/A Flagship Ventures Fund V General Partner LLC 10% owner Other BUY $15.00 165,000 $2,475,000 1,143,177 +16.9%
2020-10-21 03:07 2020-10-16 CDAK N/A ARCH Venture Fund VIII, L.P. 10% owner Other BUY $15.00 235,000 $3,525,000 2,503,903 +10.4%
2020-10-21 01:07 2020-10-16 SELB Cartesian Therapeutics, Inc. SPRINGER TIMOTHY A Director, 10% owner Pharmaceutical Preparations BUY $2.30 1,887,696 $4,336,226 10,836,256 +21.1%
2020-10-19 23:15 2020-10-19 ARRY Array Technologies Inc. Forth John Bradford Director Miscellaneous Manufacturing Industries BUY $22.00 60,924 $1,340,328 60,924 +100.0%
2020-10-19 23:15 2020-10-19 ARRY Array Technologies Inc. Bolland Stuart M. Officer - Chief Operations Officer Miscellaneous Manufacturing Industries BUY $22.00 53,461 $1,176,142 53,461 +100.0%
2020-10-19 23:15 2020-10-19 ARRY Array Technologies Inc. Krantz Jeffrey P. Officer - Chief Commercial Officer Miscellaneous Manufacturing Industries BUY $22.00 71,281 $1,568,182 71,281 +100.0%
2020-10-19 23:15 2020-10-19 ARRY Array Technologies Inc. MacVane Charlotte A. Officer - See Remarks Miscellaneous Manufacturing Industries BUY $22.00 77,221 $1,698,862 77,221 +100.0%
2020-10-20 00:54 2020-10-16 PFLEX PIMCO Flexible Credit Income Fund Class A-4 MURATA ALFRED T Other Other BUY $8.69 118,411 $1,028,992 120,831 +4,893.0%
2020-10-20 03:49 2020-08-14 FSDC Disc Medicine, Inc. FS Development Holdings, LLC 10% owner Pharmaceutical Preparations BUY $10.00 441,500 $4,415,000 441,500 +100.0%
2020-10-19 20:32 2020-10-16 VTA N/A Saba Capital Management, L.P. 10% owner Other BUY $9.35 180,136 $1,684,272 6,478,050 +2.9%
2020-10-19 23:15 2020-10-19 ARRY Array Technologies Inc. Fusaro James MacMillan Director, Officer - Chief Executive Officer Miscellaneous Manufacturing Industries BUY $22.00 182,772 $4,020,984 182,772 +100.0%
2020-10-19 23:56 2020-10-13 RADI N/A DKLDO IV Trading Subsidiary LP 10% owner Other BUY $8.00 704,337 $5,634,696 6,352,901 +12.5%
2020-10-17 01:15 2020-10-14 EBC Eastern Bankshares, Inc. Heinemann Barbara Jane Officer - Executive VP Savings Institution, Federally Chartered BUY $10.00 102,000 $1,020,000 42,000 +100.0%
2020-10-17 00:52 2020-10-14 EBC Eastern Bankshares, Inc. Sullivan Daniel J Officer - Chief Credit Officer Savings Institution, Federally Chartered BUY $10.00 100,000 $1,000,000 65,000 +100.0%
2020-10-17 00:48 2020-10-14 EBC Eastern Bankshares, Inc. Miller Jan Allan Officer - Chief Cml Banking Officer Savings Institution, Federally Chartered BUY $10.00 100,000 $1,000,000 100,000 +100.0%
2020-10-17 00:41 2020-10-14 EBC Eastern Bankshares, Inc. Fitzgerald James Burke Officer - Chief Financial Officer Savings Institution, Federally Chartered BUY $10.00 150,000 $1,500,000 17,769 +100.0%
2020-10-17 00:34 2020-10-14 EBC Eastern Bankshares, Inc. Spiess Paul Davis Director Savings Institution, Federally Chartered BUY $10.00 100,000 $1,000,000 50,000 +100.0%
2020-10-17 00:32 2020-10-14 EBC Eastern Bankshares, Inc. Shell Greg Allen Sr. Director Savings Institution, Federally Chartered BUY $10.00 200,000 $2,000,000 200,000 +100.0%
2020-10-17 00:30 2020-10-14 EBC Eastern Bankshares, Inc. Markell Peter Kenneth Director Savings Institution, Federally Chartered BUY $10.00 100,000 $1,000,000 100,000 +100.0%
2020-10-17 00:19 2020-10-14 EBC Eastern Bankshares, Inc. Bane Richard Corey Director Savings Institution, Federally Chartered BUY $10.00 120,000 $1,200,000 120,000 +100.0%
2020-10-17 00:14 2020-10-14 EBC Eastern Bankshares, Inc. Holbrook Richard Edward Director Savings Institution, Federally Chartered BUY $10.00 196,500 $1,965,000 196,500 +100.0%
2020-10-17 00:12 2020-10-14 EBC Eastern Bankshares, Inc. Rivers Robert Francis Director, Officer - Chair and CEO Savings Institution, Federally Chartered BUY $10.00 200,000 $2,000,000 200,000 +100.0%
2020-10-17 00:00 2020-08-21 HRMY Harmony Biosciences Holdings, Inc. Marshman Fund Trust II 10% owner Pharmaceutical Preparations BUY $24.00 339,476 $8,147,424 10,651,120 +3.3%
2020-10-16 22:36 2020-10-14 KRON N/A Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust 10% owner Other BUY $19.00 95,500 $1,814,500 4,370,496 +2.2%
2020-10-16 19:24 2020-10-14 SPRB SPRUCE BIOSCIENCES, INC. Muralidhar Bali Director Pharmaceutical Preparations BUY $15.00 200,000 $3,000,000 1,792,518 +12.6%
2020-10-16 19:21 2020-10-14 SPRB SPRUCE BIOSCIENCES, INC. O'Donnell Niall Director Pharmaceutical Preparations BUY $15.00 250,000 $3,750,000 695,905 +56.1%
2020-10-16 19:15 2020-10-14 SPRB SPRUCE BIOSCIENCES, INC. Omega Fund VI, L.P. Other Pharmaceutical Preparations BUY $15.00 250,000 $3,750,000 2,161,022 +13.1%
2020-10-16 19:14 2020-10-14 SPRB SPRUCE BIOSCIENCES, INC. Chaya Moghrabi Dina Director Pharmaceutical Preparations BUY $15.00 250,000 $3,750,000 2,161,022 +13.1%
2020-10-16 19:08 2020-10-14 SPRB SPRUCE BIOSCIENCES, INC. HealthCap VIII, L.P. Other Pharmaceutical Preparations BUY $15.00 250,000 $3,750,000 2,033,621 +14.0%
2020-10-16 19:07 2020-10-14 SPRB SPRUCE BIOSCIENCES, INC. HANSSON JONAS Director Pharmaceutical Preparations BUY $15.00 250,000 $3,750,000 2,033,621 +14.0%
2020-10-16 19:34 2020-10-14 SPRB SPRUCE BIOSCIENCES, INC. RiverVest Venture Fund III, L.P. 10% owner Pharmaceutical Preparations BUY $15.00 250,000 $3,750,000 2,148,281 +13.2%
2020-10-17 04:30 2020-10-16 ETON Eton Pharmaceuticals, Inc. Opaleye Management Inc. 10% owner Pharmaceutical Preparations BUY $7.00 400,000 $2,800,000 155,000 +100.0%
2020-10-17 00:22 2020-10-14 EBC Eastern Bankshares, Inc. Borgen Luis Director Savings Institution, Federally Chartered BUY $10.00 100,000 $1,000,000 46,270 +100.0%
2020-10-16 23:49 2020-10-14 SPRB SPRUCE BIOSCIENCES, INC. Novo Holdings A/S 10% owner Pharmaceutical Preparations BUY $15.00 250,000 $3,750,000 4,989,336 +5.3%
2020-10-16 22:58 2020-10-14 KRON N/A Omega Fund V, L.P. 10% owner Other BUY $19.00 450,000 $8,550,000 3,818,283 +13.4%
2020-10-16 22:56 2020-10-14 KRON N/A Stampacchia Otello Director, 10% owner Other BUY $19.00 450,000 $8,550,000 3,818,283 +13.4%
SHOW ENTRIES

Institutional Conviction in Form 4

Tracking these institutional-scale purchases allows you to follow the "smart money" when their conviction is highest. When an executive or a 10% beneficial owner commits a seven-figure sum to an open-market transaction, it bypasses the routine noise of stock-based compensation. These trades are often a precursor to major corporate developments or a signal that management views the current market valuation as significantly disconnected from the company’s internal growth trajectory. By monitoring these high-value entries, investors can align their portfolios with the capital of those who possess the most intimate understanding of a business's long-term health and potential.

Filtering the Market Noise

Our platform is designed to eliminate the noise and focus strictly on high-impact accumulation from directors and CEOs betting big on their company’s future. The SEC EDGAR database is frequently flooded with thousands of automated Form 4 filings, many of which involve small, technical, or pre-scheduled trades that offer little predictive value for the average investor. By applying a strict $1,000,000 minimum threshold, we isolate the transactions where insiders are taking substantial personal financial risk. This high-conviction filter serves as a powerful transparency tool, identifying the exact moments when corporate leadership moves away from passive ownership toward aggressive capital deployment.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.